- Home
- UTHR
as 05-08-2025 4:00pm EST
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 14.4B | IPO Year: | 1999 |
| Target Price: | $392.00 | AVG Volume (30 days): | 439.7K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 25.10 | EPS Growth: | 18.86 |
| 52 Week Low/High: | $260.41 - $417.82 | Next Earning Date: | 04-30-2025 |
| Revenue: | $2,994,100,000 | Revenue Growth: | 19.84% |
| Revenue Growth (this year): | 11.45% | Revenue Growth (next year): | 6.11% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DWEK RAYMOND | UTHR | Director | Apr 21 '25 | Sell | $285.57 | 3,000 | $856,710.00 | 1,750 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Apr 17 '25 | Sell | $282.95 | 11,000 | $3,121,543.06 | 47,381 | |
| DWEK RAYMOND | UTHR | Director | Apr 14 '25 | Sell | $285.16 | 3,000 | $855,480.00 | 1,750 | |
| DWEK RAYMOND | UTHR | Director | Apr 7 '25 | Sell | $284.55 | 4,000 | $1,138,200.00 | 1,750 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Apr 3 '25 | Sell | $304.13 | 11,000 | $3,367,983.80 | 47,381 | |
| Thompson Tommy G | UTHR | Director | Mar 24 '25 | Sell | $318.80 | 2,500 | $796,990.50 | 8,480 | |
| PATUSKY CHRISTOPHER | UTHR | Director | Mar 19 '25 | Sell | $310.89 | 5,000 | $1,553,584.58 | 3,035 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Mar 10 '25 | Sell | $319.24 | 1,900 | $607,784.75 | 400 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Mar 3 '25 | Sell | $312.82 | 9,442 | $2,944,187.16 | 400 | |
| Thompson Tommy G | UTHR | Director | Feb 28 '25 | Sell | $318.34 | 2,500 | $795,837.75 | 8,480 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
StockStory
19 hours ago
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
StockStory
2 days ago
3 Market-Beating Stocks with Solid Fundamentals
Argus Research
2 days ago
Analyst Report: United Therapeutics Corp
Argus Research
3 days ago
Market Digest: CCI, AMP, CMCSA, CME, CVS, ECL, GD, HLF, PFE, PH, UTHR, WDC, PPC
StockStory
4 days ago
Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow
Simply Wall St.
6 days ago
United Therapeutics First Quarter 2025 Earnings: Beats Expectations
Zacks
7 days ago
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
GuruFocus.com
8 days ago
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.